BioXcel Therapeutics, Inc. (BTAI) News
Filter BTAI News Items
BTAI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BTAI News Highlights
- BTAI's 30 day story count now stands at 11.
- Over the past 15 days, the trend for BTAI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about BTAI are CONN, MRK and NE.
Latest BTAI News From Around the Web
Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and w |
BioXCel agitation with bipolar drug meets primary and secondary endpoints in phase 3BioXCel Therapeutics (BTAI) said that a phase 3 trial of BXCL501 (sublingual dexmedetomidine) for agitation associated with bipolar disorder demonstrated statistically significant changes. |
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar DisordersBXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo BXCL501 PDUFA Date is April 5, 2022 for acute treatment of agitation associated with schizophrenia and bipolar disorders NEW HAVEN, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in ne |
BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate CancerBioXcel Therapeutics Inc (NASDAQ: BTAI ) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. Results will be highlighted in two poster presentations at the 2022 ASCO Genitourinary Cancers Symposium. The trial is evaluating the combination of BXCL701 with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab). SCNC Findings: In the evaluable patient cohort (n = 15), |
IQVIA Holdings' Q4 Beats Street View, Lifts FY22 Earnings GuidanceView more earnings on IQVSee more from BenzingaBioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate CancerHenry Schein Q4 Topline, Bottom Line Beat Street View, FY22 Outlook Exceeds Consensus© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. |
BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers SymposiumBXCL701 plus KEYTRUDA ® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts |
What Type Of Shareholders Own The Most Number of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares?If you want to know who really controls BioXcel Therapeutics, Inc. ( NASDAQ:BTAI ), then you'll have to look at the... |
BioXcel Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceNEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will present at the upcoming SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16 at 2:20 p.m. ET. Dr. Mehta will highlight the Company’s neuroscience and immuno-oncology programs, artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process, and its commercial and launch readiness plans for BXCL501. |
BioXcel Therapeutics Appoints Matt Wiley Chief Commercial OfficerNEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO). “We are pleased to welcome Matt to our management team, as we prepare for our first potential approval and commercial launch of BXCL501 f |
BioXcel Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceNEW HAVEN, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present corporate updates and plans for 2022 at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, on Thursday, January 13, 2022 at 9:45 a.m. ET. T |